NCT06418698 The Correlation of Intracranial Artery Calcification and Outcomes of Mechanical Thrombectomy
| NCT ID | NCT06418698 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Zhujiang Hospital |
| Condition | Stroke, Acute |
| Study Type | OBSERVATIONAL |
| Enrollment | 434 participants |
| Start Date | 2024-03-28 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 434 participants in total. It began in 2024-03-28 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
CAIS-MT is a single-center, prospective cohort study, to evaluate the correlation between outcomes of endovascular treatment(EVT) and intracranial artery calcification(IAC) in patients with acute ischemic stroke due to large or medium vessel occlusion.
Eligibility Criteria
Inclusion Criteria: * Male or non-pregnant women with acute stroke symptoms aged over 18 years. * Occlusion of the intracranial internal carotid artery, the middle cerebral artery, the anterior cerebral artery, the posterior cerebral artery, basilar artery and intracranial vertebral artery confirmed by CT, MR angiography, or digital subtraction angiography. * No absolute contraindication to iodinated contrast media. * Planned treatment with EVT by clinical care team. * Informed consent obtained from patients or their legal representatives. * Willing to be followed up as required by the clinical study protocol. Exclusion Criteria: * Acute ischemic stroke occurs over 24 hours of time last known well. * Neurologic deficits caused by diagnoses other than ischemic stroke, such as intracerebral hemorrhage, subarachnoid hemorrhage, or intracranial tumors. * With other underlying factors leading to IAC, such as hyperthyroidism, end-stage renal disease, long-term oral intake of vitamin K antagonist(Warfarin), chronic vitamin D deficiency or overdose, persistent hypomagnesemia, persistent hypercalcemia, persistent hyperphosphatemia and high oral calcium intake. * Lack of non-contract CT images on admission and significant artifacts in CT images preventing IAC measurement. * Severe renal insufficiency (estimated glomerular filtration rate \< 30ml/min or serum creatinine \> 220μmol/L (2.5mg/dl)). * Previous cerebrovascular intervention treatment or craniotomy.
Contact & Investigator
Duan Chuanzhi, MD
PRINCIPAL INVESTIGATOR
Zhujiang Hospital
Frequently Asked Questions
Who can join the NCT06418698 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Stroke, Acute. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06418698 currently recruiting?
Yes, NCT06418698 is actively recruiting participants. Contact the research team at 13681134001@163.com for enrollment information.
Where is the NCT06418698 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT06418698 clinical trial?
NCT06418698 is sponsored by Zhujiang Hospital. The principal investigator is Duan Chuanzhi, MD at Zhujiang Hospital. The trial plans to enroll 434 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.